论文部分内容阅读
目的观察瑞舒伐他汀对急性冠状动脉(冠脉)综合征(ACS)患者经皮冠状动脉介入治疗(PCI)术后的临床疗效。方法 108例接受PCI治疗的ACS患者,随机分为A、B、C三组,各36例。A组术前每晚口服40 mg阿托伐他汀,术后每晚口服20 mg,连续服用6个月;B组术前每晚口服40 mg辛伐他汀,术后每晚口服20 mg,连续服用6个月;C组术前每晚口服20 mg瑞舒伐他汀,术后每晚口服10 mg,连续服用6个月。观察三组治疗前后血脂水平及心肌酶谱水平的变化情况。结果 C组治疗后血脂水平及心肌酶谱水平下降程度均明显优于A组和B组,差异具有统计学意义(P<0.05)。结论瑞舒伐他汀对ACS患者PCI术后降脂和心肌酶作用较等效剂量的阿托伐他汀或辛伐他汀效果更好。
Objective To observe the clinical effect of rosuvastatin on patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). Methods A total of 108 ACS patients undergoing PCI were randomly divided into three groups: A, B and C, with 36 cases in each. In group A, 40 mg of atorvastatin orally was given orally every night and 20 mg orally daily for 6 months. In group B, 40 mg of simvastatin was administered orally every night before operation and 20 mg orally every night Taking 6 months. In group C, rosuvastatin 20 mg orally every night was given orally 10 mg orally daily for 6 months. The changes of serum lipids and myocardial enzymes before and after treatment were observed. Results After treatment, the level of lipids and the level of myocardial enzymes decreased significantly in group C compared with those in group A and group B, the difference was statistically significant (P <0.05). Conclusions Rosuvastatin is more effective than atorvastatin or simvastatin on lipid lowering and myocardial enzyme in ACS patients after PCI.